Prominent Perspective on Existing Biological Hallmarks of Alzheimer's Disease

Overview

Journal Curr Top Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2024 Apr 9

PMID 38591203

Authors

Namrata Singh

Srishti Sharma

Kallol K Ghosh

Bhanushree Gupta

Kamil Kuca

Affiliations

Soon will be listed here.

Abstract

Biomarkers are the most significant diagnosis tools tending towards unique approaches and solutions for the prevention and cure of Alzheimer's Disease (AD). The current report provides a clear perception of the concept of various biomarkers and their prominent features through analysis to provide a possible solution for the inhibition of events in AD. Scientists around the world truly believe that crucial hallmarks can serve as critical tools in the early diagnosis, cure, and prevention, as well as the future of medicine. The awareness and understanding of such biomarkers would provide solutions to the puzzled mechanism of this neuronal disorder. Some of the argued biomarkers in the present article are still in an experimental phase as they need to undergo specific clinical trials before they can be considered for treatment.

References

Wang S, Liu Y, Zhu A, Tian Y . In Vivo Electrochemical Biosensors: Recent Advances in Molecular Design, Electrode Materials, and Electrochemical Devices. Anal Chem. 2023; 95(1):388-406. DOI: 10.1021/acs.analchem.2c04541. View

Li J, Ni W, Jin D, Yu Y, Xiao M, Zhang Z . Nanosensor-Driven Detection of Neuron-Derived Exosomal Aβ with Graphene Electrolyte-Gated Transistor for Alzheimer's Disease Diagnosis. Anal Chem. 2023; 95(13):5719-5728. DOI: 10.1021/acs.analchem.2c05751. View

Sharma S, Singh N, Nepovimova E, Korabecny J, Kuca K, Satnami M . Interaction of synthesized nitrogen enriched graphene quantum dots with novel anti-Alzheimer's drugs: spectroscopic insights. J Biomol Struct Dyn. 2019; 38(6):1822-1837. DOI: 10.1080/07391102.2019.1619625. View

Xu L, Lai L, Wen Y, Lin J, Chen B, Zhong Y . Angiopep-2, an MRI Biomarker, Dynamically Monitors Amyloid Deposition in Early Alzheimer's Disease. ACS Chem Neurosci. 2023; 14(2):226-234. PMC: 9854622. DOI: 10.1021/acschemneuro.2c00513. View

Sharma S, Banjare M, Singh N, Korabecny J, Kuca K, Ghosh K . Multi-spectroscopic monitoring of molecular interactions between an amino acid-functionalized ionic liquid and potential anti-Alzheimer's drugs. RSC Adv. 2022; 10(64):38873-38883. PMC: 9057349. DOI: 10.1039/d0ra06323a. View

Duan R, Hong C, Chen M, Wang X, Pang Z, Xie H . Targeting autophagy receptors OPTN and SQSTM1 as a novel therapeutic strategy for osteoporosis complicated with Alzheimer's disease. Chem Biol Interact. 2023; 377:110462. DOI: 10.1016/j.cbi.2023.110462. View

Leng H, Yang J, Long L, Yan Y, Shi W, Zhang L . GFP-based red-emissive fluorescent probes for dual imaging of β-amyloid plaques and mitochondrial viscosity. Bioorg Chem. 2023; 136:106540. DOI: 10.1016/j.bioorg.2023.106540. View

Auso E, Gomez-Vicente V, Esquiva G . Biomarkers for Alzheimer's Disease Early Diagnosis. J Pers Med. 2020; 10(3). PMC: 7563965. DOI: 10.3390/jpm10030114. View

Wang M, Tang G, Zhou C, Guo H, Hu Z, Hu Q . Revisiting the intersection of microglial activation and neuroinflammation in Alzheimer's disease from the perspective of ferroptosis. Chem Biol Interact. 2023; 375:110387. DOI: 10.1016/j.cbi.2023.110387. View

10.

Reitz C, Brayne C, Mayeux R . Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011; 7(3):137-52. PMC: 3339565. DOI: 10.1038/nrneurol.2011.2. View

11.

Yun S, Cho S, Jo C, Park M, Han C, Koh Y . Elevation of plasma soluble amyloid precursor protein beta in Alzheimer's disease. Arch Gerontol Geriatr. 2019; 87:103995. DOI: 10.1016/j.archger.2019.103995. View

12.

Tang K, Hynan L, Baskin F, Rosenberg R . Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease. J Neurol Sci. 2005; 240(1-2):53-8. PMC: 1479090. DOI: 10.1016/j.jns.2005.09.002. View

13.

Delaby C, Hirtz C, Lehmann S . Overview of the blood biomarkers in Alzheimer's disease: Promises and challenges. Rev Neurol (Paris). 2022; 179(3):161-172. DOI: 10.1016/j.neurol.2022.09.003. View

14.

Sunderland T, Mirza N, Putnam K, Linker G, Bhupali D, Durham R . Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatry. 2004; 56(9):670-6. DOI: 10.1016/j.biopsych.2004.07.021. View

15.

Cedazo-Minguez A, Winblad B . Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects. Exp Gerontol. 2009; 45(1):5-14. DOI: 10.1016/j.exger.2009.09.008. View

16.

Assini A, Cammarata S, Vitali A, Colucci M, Giliberto L, Borghi R . Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology. 2004; 63(5):828-31. DOI: 10.1212/01.wnl.0000137040.64252.ed. View

17.

Borroni B, Di Luca M, Padovani A . Predicting Alzheimer dementia in mild cognitive impairment patients. Are biomarkers useful?. Eur J Pharmacol. 2006; 545(1):73-80. DOI: 10.1016/j.ejphar.2006.06.023. View

18.

Brettschneider S, Morgenthaler N, Teipel S, Fischer-Schulz C, Burger K, Dodel R . Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide. Biol Psychiatry. 2005; 57(7):813-6. DOI: 10.1016/j.biopsych.2004.12.008. View

19.

Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M . CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016; 15(7):673-684. DOI: 10.1016/S1474-4422(16)00070-3. View

20.

Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C . Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem. 2001; 47(10):1776-81. View